(Q35085370)

6 August 2017

1 reference

title

Weight management and current options in pharmacotherapy: orlistat and sibutramine (English)

1 reference

6 August 2017

0 references

Wilson Y S Leung

1

1 reference

6 August 2017

G Neil Thomas

series ordinal

2

1 reference

6 August 2017

Juliana C N Chan

series ordinal

3

1 reference

6 August 2017

Brian Tomlinson

series ordinal

4

1 reference

6 August 2017

language of work or name

1 reference

1 January 2003

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

58-80

1 reference

Guidelines for Healthy Weight

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Are overweight children unhappy?: Body mass index, depressive symptoms, and overweight concerns in elementary school children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Body mass index and cardiovascular risk factors in a rural Chinese population.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Appetite suppressants. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Phenylpropanolamine and the risk of hemorrhagic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of managed care on medical education

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Lack of interaction between orlistat and oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine produces dose-related weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine in weight control: a dose-ranging, efficacy study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine reduces food intake in non-dieting women with obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Thermogenic effects of sibutramine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine pharmacokinetics in young and elderly healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Long-term weight loss with sibutramine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Appetite suppressants and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990009-9

7 January 2021

10.1016/S0149-2918(03)90009-9

Identifiers

DOI

1 reference

6 August 2017

1 reference